Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Halozyme Therapeutics, Inc.

NASDAQ: HALO · Life Sciences · 10 alerts · CIK 1159036

Share price
$96.50Close, Nov 16
Market cap
$11B
Shares outstanding
114.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Halozyme Therapeutics, Inc. filings on SEC EDGAR ↗

8:34 PM ET Form 4
Insider Selling

Halozyme Therapeutics President and CEO Helen Torley Sells $6M of Stock

Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $96.85 to $101.72 a share (average $100.01) in 10 transactions, worth $6M in total between Nov 12, 2026 and Nov 16, 2026. Shares held after the trade: 767,780 (-0.0%).

Value
$6M
Shares
60,000
Average price
$100.01
Role
President and CEO
Holding change
-0.0%
Trade date
Nov 12, 2026 to Nov 16, 2026
7:56 PM ET Form 4
Insider Selling

Halozyme Therapeutics President and CEO Helen Torley Sells $6.61M of Stock

Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.90 to $113.69 a share (average $110.18) in 12 transactions, worth $6.61M in total between Oct 6, 2026 and Oct 8, 2026. Shares held after the trade: 767,780 (-0.0%).

Value
$6.61M
Shares
60,000
Average price
$110.18
Role
President and CEO
Holding change
-0.0%
Trade date
Oct 6, 2026 to Oct 8, 2026
4:38 PM ET Form 4
Insider Selling

Halozyme Therapeutics Insider Matthew L. Posard Sells $568K of Stock

Matthew L. Posard sold 5,230 shares of Halozyme Therapeutics, Inc. at $107.17 to $110.04 a share (average $108.54) in 4 transactions, worth $568K in total on Oct 1, 2026. Shares held after the trade: 53,609 (-0.2%).

Value
$568K
Shares
5,230
Average price
$108.54
Holding change
-0.2%
Trade date
Oct 1, 2026
9:08 AM ET Form 4
Insider Selling

Halozyme Therapeutics President and CEO Helen Torley Sells $6.44M of Stock

Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.01 to $108.67 a share (average $107.28) in 7 transactions, worth $6.44M in total between Sep 9, 2026 and Sep 11, 2026. Shares held after the trade: 767,780 (-0.6%).

Value
$6.44M
Shares
60,000
Average price
$107.28
Role
President and CEO
Holding change
-0.6%
Trade date
Sep 9, 2026 to Sep 11, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.